What the trial was testing
The MYR 301 enrolled 150 patients with liver disease. The study was sponsored by Gilead Sciences and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
45-48% of patients had major virus reductions and normal liver inflammation markers, compared to just 2% without treatment.
The New England journal of medicine · 2023 · NCT03852719
These findings — that had big drops in virus levels and normal liver markers vs. 2% without treatment — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 150 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with liver disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Bulevirtide was FDA-approved in 2024 for chronic hepatitis D in adults. If you have hepatitis D, ask your doctor whether this treatment is right for you. The drug is given as a daily injection under the skin.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open liver disease trials
Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
Development of a FibroScan Liver Examination Using a Single Probe
This is an exploratory, international, prospective, interventional, multicenter clinical investigation that will take place in 1 Hong Kong site and 3 French sites and 309 adults patients will be included. The study objective is to assess the LSM reproducibility between the FibroScan examination performed with the Single Probe (SP) and the FibroScan examination performed with the reference probes (M and XL).